- Home
- ECX vs VERV Comparison
ECX vs VERV Comparison
Compare ECX & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- VERV
- Stock Information
- Founded
- ECX 2017
- VERV 2018
- Country
- ECX China
- VERV United States
- Employees
- ECX N/A
- VERV N/A
- Industry
- ECX EDP Services
- VERV Medicinal Chemicals and Botanical Products
- Sector
- ECX Technology
- VERV Health Care
- Exchange
- ECX Nasdaq
- VERV Nasdaq
- Market Cap
- ECX 584.9M
- VERV 475.0M
- IPO Year
- ECX N/A
- VERV 2021
- Fundamental
- Price
- ECX $1.82
- VERV $5.61
- Analyst Decision
- ECX
- VERV Strong Buy
- Analyst Count
- ECX 0
- VERV 4
- Target Price
- ECX N/A
- VERV $25.75
- AVG Volume (30 Days)
- ECX 355.8K
- VERV 1.6M
- Earning Date
- ECX 11-07-2024
- VERV 11-05-2024
- Dividend Yield
- ECX N/A
- VERV N/A
- EPS Growth
- ECX N/A
- VERV N/A
- EPS
- ECX N/A
- VERV N/A
- Revenue
- ECX $778,608,168.00
- VERV $24,396,000.00
- Revenue This Year
- ECX $20.12
- VERV $97.47
- Revenue Next Year
- ECX $32.70
- VERV N/A
- P/E Ratio
- ECX N/A
- VERV N/A
- Revenue Growth
- ECX 25.45
- VERV 219.91
- 52 Week Low
- ECX $0.96
- VERV $4.31
- 52 Week High
- ECX $3.44
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- ECX 46.50
- VERV 46.58
- Support Level
- ECX $1.89
- VERV $5.19
- Resistance Level
- ECX $2.02
- VERV $7.40
- Average True Range (ATR)
- ECX 0.11
- VERV 0.68
- MACD
- ECX -0.00
- VERV -0.09
- Stochastic Oscillator
- ECX 8.33
- VERV 17.17
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services primarily in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.